Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 … – Nasdaq
|
Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 …
Nasdaq SEATTLE and SOUTH SAN FRANCISCO, March 12, 2018 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced updated data from two separate trials evaluating its lead … |
